SAB Biotherapeutics Inc (NASDAQ: SABS) announced that the first HUMAN trial participants (Fully HUman anti-thymocyte biologic in a first-in-MAN clinical study) have been dosed in Australia. This Phase 1 randomized, double-blind, placebo-controlled, single-ascending dose, adaptive design clinical study was designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous SAB-142 in healthy volunteers and participants with type-1 diabetes (T1D). SAB-142 is a first-
Related Keywords
Australia , , Sab Biotherapeutics Inc , Biological Activity , Investigational New Drug , Stock Market Game , Benzinga Pro , Day Trial , Kickstarts Phase , For Its Lead Type , Hopeful In Australia , Biotherapeutics , Clinical Study , Labs , Immune Cells ,
vimarsana.com © 2020. All Rights Reserved.